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Objective: Evidence-based guidelines recommend adjuvant chemotherapy in early stage 
breast cancer whenever treatment benefit is considered sufficient to outweigh the associated 
risks. However, many groups of patients were either excluded from or underrepresented in 
the clinical trials that form the evidence base for this recommendation. This study aims to 
determine whether using administrative healthcare data – Real World Data (RWD) - and 
econometric methods for causal analysis to provide ‘Real World Evidence’ (RWE) are 
feasible methods for addressing this gap. 
Methods: Cases of primary breast cancer in women from 2001 to 2015 were extracted from 
the Scottish cancer registry (SMR06) and linked to other routine health records (inpatient 
and    outpatient visits). Four methods were used to estimate the effect of adjuvant 
chemotherapy on disease-specific and overall mortality: (1) regression with adjustment for 
covariates (2) propensity score matching (3) instrumental variables analysis and (4) 
regression discontinuity design. Hazard ratios for breast cancer mortality and all-cause 
mortality were compared to those from a meta-analysis of randomised trials. 
Results: 39,805 cases included in the analyses. Regression adjustment, propensity score 
matching and instrumental variables were feasible while regression discontinuity was not. 
Effectiveness estimates were similar between RWE and randomised trials for breast cancer 
mortality but not for all-cause mortality. 
Conclusions: RWE methods are a feasible means to generate estimates of effectiveness of 
adjuvant chemotherapy in early stage breast cancer. However, such estimates must be 
interpreted in the context of the available randomised evidence and the potential biases of 
the observational methods.  
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?????????????
Adjuvant chemotherapy is indicated in cases of early stage breast cancer whenever 
treatment benefit is considered sufficient to outweigh the associated risks (1). The benefits 
of chemotherapy, in terms of improved survival and disease free survival, are known to vary 
on a case by case basis depending on a number of prognostic markers. Likewise, the risks 
of chemotherapy vary depending on the characteristics of the patient (2). Patients, with 
advice from their clinicians, must choose whether or not to undergo adjuvant chemotherapy 
taking account of these individual factors and their own beliefs and preferences. The shared 
decision making process requires a patient specific risk assessment and the effective 
communication of patient preference, risks, and benefits information between the clinician 
and the patient. To facilitate this process and help improve decisions a number of tools have 
been developed that quantify the risks and benefits of the available treatments (3-5). Data 
from randomised controlled trials (RCTs) are the primary source for decision making tools 
however these are limited by strict patient inclusion criteria, leading to concerns about 
whether treatment benefit estimates are accurate for all patients (generalisability). It is 
proposed that real world evidence (RWE) can contribute to informing these decisions by 
providing accurate treatment benefit estimates from more representative real world data (6).  
Real world data (RWD) refers to data used for decision making that are collected outside of 
randomised controlled trials (RCTs) (7). RCTs are the gold standard for reliably measuring 
treatment efficacy and constitute the primary source of evidence to inform decision-making 
in health care. Randomisation, correctly implemented (8), guarantees unbiased estimates of 
the average treatment effect (in expectation) by ensuring balance of observed and 
unobserved covariates in treatment and control groups. Real world data in contrast are 
observational in nature and therefore subject to additional sources of bias (9). Methods of 
analysis, ‘designs’, have been developed to allow less biased estimates of treatment effects 
under reasonable assumptions. These methods have contributed to the ‘credibility 
revolution’ in economics (10) and have led some to re-evaluate existing hierarchies of 
evidence in medicine (11). 
The “quasi-experimental” methods available to researchers differ in the mechanisms used to 
mirror random assignment; historically the greatest limitations to their application have been 
data availability and quality, and concerns about the feasibility of more advanced methods. 
This study makes use of high quality routine data to implement alternative candidate 
methods and compare estimates both between methods and with the available RCT 
evidence. The randomised evidence comes from a series of progressively updated meta-
analyses published by the Early Breast Cancer Trialists Collaborating Group (EBCTCG) (2, 
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12, 13). Results from the most recent meta-analysis are used make comparisons with the 
RWE estimates from this study.   
We consider four candidate methods: 
1. Regression with adjustment for covariates (RA): Uses multiple regression based 
methods to adjust for the imbalance in observed covariates between treated and 
untreated cases.  
2. Propensity score matching (PSM) (14): Uses rich prognostic data to create 
propensity scores and match treated and untreated cases, reducing confounding by 
indication  
3. Instrumental variables (IV) (15): Makes use of variables that are assumed to causally 
affect the treatment decision but have no effect on outcomes other than indirectly, via 
changing the probability of treatment. 
4. Regression discontinuity design (RDD) (16): Exploits the variation in treatment use 
created by a treatment guideline based on a threshold level of estimated treatment 
benefit provided by an online tool. 
This study aims to explore the feasibility, and compare the results of RWE methods for 
estimating the effectiveness of adjuvant chemotherapy for early stage breast cancer. Due to 
the reasonable concerns about bias in RWE methods the approach we have taken is 
exploratory in nature and seeks to provide extensive contextual information to inform the 
judgements of readers on the interpretation of RWE estimates. We believe such an open 
approach, which differs from the typical ‘stand alone’ inference of a randomised trial, is 
necessary if RWE is to be useful for informing patient and clinician decision making in this 
setting. 
A key feature of this study is that all methods make use of prognostic and treatment benefit 
predictions about individual women provided by an online prognostication and treatment 
benefit tool for patients with early stage breast cancer - PREDICT (5).  
Some RWE methods have previously been employed in this setting. PSM was used with a 
large observational study conducted in the USA (17) comparing mastectomy and breast 
conserving surgery in node negative patients using a registry data set. The results 
corresponded closely with previously reported trials and provided evidence that the 
estimated hazard ratios could be generalised beyond trial populations, and this information 
was influential for clinical practice. The success of PSM for comparing surgical strategies in 
the same patient group is one reason to believe PSM might also be appropriate for 
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addressing questions relating to the effectiveness of adjuvant therapies. Other PSM studies 
focusing on adjuvant therapies have not made comparisons with randomized data.1  
Application of RDD for the evaluation of healthcare interventions has recently received 
increased attention and there are some successful examples of this method (18). However, 
the application of RDD to this clinical area is, to the best of our knowledge, completely novel. 
????????
?????????????
Patient level data were transferred into the National Services Scotland Safe Haven as an 
extract from the Scottish Cancer Registry (SCR). All records in the registry with a diagnosis 
of primary invasive breast cancer (ICD-10 C50) diagnosed in the period between January 
2001 and December 2015 were retrieved for analysis. SCR is a population-based registry 
that covers all residents of Scotland (population approximately 5.5 million). National Records 
of Scotland provides notification of deaths for registry records. Vital status was recorded up 
to 1st February 2017 in the analysis extract2. Deaths due to breast cancer were defined in 
accordance with the ICD-10 coding system for causes of death, recorded either as the 
primary cause of death or as one of three contributing causes of death. Data were restricted 
to the first occurrence of a primary breast cancer for each patient, subsequent primary 
breast cancers were excluded. Data linkage was provided by Information Services Division 
(ISD) to Scottish hospital inpatient and day case records (SMR01) and outpatient records 
(SMR00). Deterministic linkage was achieved using the Community Health Index (CHI) 
number unique individual identifiers, which includes a check digit. The linked data sets 
included all records linked to an included registry case from the period up to 5 years prior to 
the date of diagnosis. Prognostic factors available for use in the analysis, including the 
derived PREDICT scores, are described in detail in the supplementary appendix (SA1).  
Details of the use of PREDICT scores in each method are displayed in table 1. In the RA, 
PSM and IV methods PREDICT version 2 scores were used. ‘Prognostic score’ was the 
PREDICT probability of death from any cause over 10 years. In models with breast cancer 
specific mortality as the outcome this was the probability of death due to breast cancer over 
10 years. PREDICT benefit score was the difference in the probability of survival at 10 years 
following diagnosis with and without adjuvant chemotherapy. 
                                                 
1 PSM has also previously been applied to estimate adjuvant chemotherapy effectiveness in a large case series 
from a single institution in France (18). PSM has also been used for estimating the effects of adjuvant 
chemotherapy for older women (19, 20) (a specific trial ineligible group) in data from the USA   . 
2 For those emigrating from Scotland a date of embarkation is available allowing censoring these observations at 
the appropriate time. 
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Cases were excluded if the patient was male, had advanced cancer (clinical M stage = 1), 
did not receive surgery or received neoadjuvant therapy (chemotherapy or hormone therapy 
recorded prior to surgery).  
Because some groups of patients such as the over 70s and those with comorbidities, were 
either excluded from, or underrepresented in, the randomised trials, we made a comparison 
with a subgroup of RWE patients who would meet trial inclusion criteria as well as with the 
full cohort. Cases were defined as ‘trial represented’ (TR) if they were under 70 years of age 
with no recorded Charlson comorbidities, and met criteria related to prognostic factors; either 
node positive or with 2 or more of: [1] >30mm tumour size, [2] grade 3, [3] ER-, and [4] 
Her2+ status. The definition of trial represented was based on assessment of the protocols 
of a number of trials in the meta-analysis (2) and clinical expert opinion. It should be noted 
that trial inclusion/exclusion protocols varied to some degree and often included elements of 
clinical judgement. 
???????????? ???????
All analyses were repeated for two outcomes; breast cancer specific mortality and all-cause 
mortality as recorded on death certificates. Furthermore, the analyses were repeated in the 
full cohort and the TR subgroup. Each method of analysis therefore produced four estimated 
hazard ratios. The details of the implementation are reported in the supplementary appendix 
(SA2). 
Table 1 - Use of person-specific PREDICT scores in the four RWE methods 
Method How PREDICT outputs were used:
Regression Adjustment PREDICT Prognostic score and benefit 
score were used as explanatory variables. 
This effectively includes prognostic variable 
interactions and transforms informed by 
external evidence (from derivation cohort 
and previous studies that informed the 
specification used in PREDICT modelling). 
Propensity Score Matching Prognostic score and benefit scores were 
used as explanatory variables in the 
propensity score model.  
Instrumental Variables PREDICT benefit score was used as an 
instrument. Benefit score interacted with 
post-2010 dummy variable used as an 
alternative instrument. Prognostic score is 
an (independent) explanatory variable. 
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Regression Discontinuity Benefit score used as the continuous 
assignment variable 
??????????? ???????????????????????
Clinical expert opinion suggests that the predominant chemotherapy regimens in use in 
Scotland during the 2001-2015 period were newer anthracycline-containing regimens 
(CAF/CEF), therefore estimates for these types of regimen were used as the best 
comparison with the RWE estimates. Both direct evidence, from trials comparing newer 
anthracycline-containing regimens vs. placebo, and indirect evidence via trials of newer 
anthracycline-containing regimens vs. other active regimens were considered. This required 
some re-analysis using the trial level summary statistics presented in (2) as a network meta-
analysis (19). In the primary analysis versus RWE methods the comparison was made using 
only direct trial evidence. 
To compare RWE with randomised evidence two approaches were taken. First, a statistical 
test of the difference in the estimated treatment effect between trial and observational 
sources based on z scores, as suggested by Ioannidis et al (20). z scores above 1.96 or 
below -1.96 are considered as sufficient evidence that the difference in estimates is beyond 
that expected by chance. Second, meta-analysis estimates were calculated with and without 
inclusion of RWE estimates. Results were presented in forest plots to allow visual 
assessment of heterogeneity. A random effects model was assumed because of known 
between-trial and trial-observational differences in study populations. Cochrane’s Q was 
used as a statistical test of heterogeneity. 
????????
?????????????????
63,116 records were retrieved from the registry. Following removal of duplicate records 
(non-first cancers and multiple synchronous tumours) and application of the exclusion 
criteria a total of 39,805 cases remained in the primary analysis. The process is detailed in 
figure 1. 13% of otherwise eligible cases contained missing prognostic variable data but in 
most cases only a single variable was missing. A summary of sample characteristics can be 
found in Table 2.   
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Figure 1 - Sample selection flow diagram 
?
Table 2 - Sample Characteristics 
Full cohort Trial representative 
cohort 
Total number of subjects 39,805 12,870 
Total time at risk (years) 278,984 93,222 
Median follow-up (years) 6.35 6.64 
Number of breast cancer deaths 4,977 2,126 
Number of other deaths 3,624 511 
Five-year breast cancer survival rate 87.1% 86.8% 
Median age at diagnosis, years 61 54 
Number  (%) Number  (%) 
Age <35 503 1.3 321 2.5 
35-49 7015 17.6 3879 30.1 
50-64 16792 42.2 6655 51.7 
65-74 9797 24.6 2015 15.7 
Records retrieved 
from registry,        
n = 63,116
Duplicate records 
removed, 
n = 1,680 
Without duplicates,
n = 61,436
 Final complete 
case sample,
n = 39,805
Ineligible cases 
removed, 
Advanced: 3,039 
Male: 345 
No surgery: 8,063 
Neo-adjuvant: 4,201 
(applied sequentially) 
Cases with missing 
variables, n = 5,983
Cases meeting 
inclusion criteria, 
 n = 45,788
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>=75 5698 14.3 0 0 
Nodes 0 26275 66 3294 25.6 
Nodes 1 5747 14.4 4154 32.3 
Nodes 2-4 4456 11.2 3202 24.9 
Nodes 5-9 1635 4.1 1079 8.4 
Nodes 10+ 1453 3.7 978 7.6 
Tumour size <10mm 5453 13.7 717 5.6 
10-19mm 15774 39.6 3907 30.4 
20-29mm 10727 26.9 4029 31.3 
30-49mm 5967 15 3146 24.4 
>=50mm 1884 4.7 1071 8.3 
Grade I 5866 14.7 758 5.9 
II 19130 48.1 4473 34.8 
III 14606 36.7 7564 58.8 
ER- 6208 15.6 3900 30.3 
ER+ 33597 84.4 8970 69.7 
Chemotherapy 14589 36.7 10439 81.1 
Hormone therapy 29991 75.3 7822 60.8 
Chemo + hormone therapy 8875 22.3 6060 47.1 
Screen detected 14887 37.4 3602 28 
Symptomatic 24827 62.4 9205 71.5 
Charlson Index >= 1 2455 6.2 0 0 
Charlson Index = 0 37350 93.8 12870 100 
SIMD deprivation quintile 1 (most 
deprived 
6893 17.3 2377 18.5 
SIMD 2 7823 19.7 2480 19.3 
SIMD 3 8478 21.3 2705 21 
SIMD 4 8300 20.9 2719 21.1 
SIMD 5 (least deprived) 8310 20.9 2588 20.1 
<3% Chemo benefit PREDICT 24475 61.5 3357 26.1 
3-5% 8382 21.1 4570 35.5 
>5% 6948 17.5 4943 38.4 
Mean s.d. Mean s.d. 
Age  60.72 0.067 53.47 0.089 
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Tumour size  22.03 0.076 27.02 0.149 
Total inpatient days 2.88 0.065 1.35 0.061 
Total outpatient visits 6.2 0.048 5.33 0.07 
PREDICT benefit score 2.93 0.012 4.66 0.02 
s.d.: standard deviation. 
????????????
RA using Cox regression was feasible in both TR and full cohort groups. PSM was also 
determined to be feasible. The distribution of propensity scores are displayed in 
supplementary appendix (SA3). The region of common support was sufficient in both the 
trial represented and full cohort groups. The balance of baseline covariates between 
matched treated and non-treated units in both groups was compared for each matching 
method (SA3).  PSM 1 showed some imbalances for the TR group and more severe 
imbalance in the full cohort. PSM 2 achieved good balance in the TR but not in the full 
cohort. PSM 3 achieved good balance for both TR and full cohorts. Consequently, PSM 3 
was selected as the primary analysis. Results for all PSM methods are available in appendix 
SA3.  
Both IV approaches demonstrated feasibility. The first-stage regression results are displayed 
in appendix SA4. Both instruments showed promise through statistically significant 
associations with chemotherapy use in the first stage regressions. Note that much of the 
variation in chemotherapy use caused by the instruments may be in node negative patients 
who would not meet the defined trial represented criteria, therefore these instruments may 
be more powerful in the full cohort.  
RDD was not feasible. Inspection of histograms confirmed that the requirement of continuity 
in the region of the 3% and 5% thresholds was met for PREDICT v2 but not v1.2 (figures 
SA5.1 and SA5.2), eliminating PREDICT 1.2 as a candidate assignment variable.  
The PREDICT version 2 benefit score with 3% and 5% thresholds had potential for an RDD. 
To determine whether or not treatment guidelines and norms actually create such a 
discontinuity we inspected the binned scatterplots displayed in Figures SA5.3 and S5.4, to 
visualise the relationship between the assignment variable and the probability of 
chemotherapy use. 
The binned scatterplots show no clear discontinuity in the probability of using chemotherapy 
at the 3% or 5% thresholds in the trial represented group. The plots suggest that the 
probability of chemotherapy use is already high by 3% chemotherapy benefit and increases 
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only gradually past this threshold. Based on these core assumptions not being met, 
estimation of the treatment effect using RDD was halted.  
??????????? ?????????? ????????????????? ?????
Full details of the randomised trial evidence and network meta-analysis (NMA) results are in 
the Supplementary Appendix (SA6). Comparisons are made with only the direct randomised 
evidence to simplify the analysis and presentation, and because the NMA results indicate 
little difference from including the indirect evidence. All the preceding RWE estimates of the 
effectiveness of adjuvant chemotherapy are summarised together in table 6, together with 
the combined estimates from a random effects meta-analysis and results of a test of the 
difference in estimated HR between RWE and trial meta-analysis. Forest plots displaying the 
estimated HRs for individual trials and RWE methods are displayed in figure 2. Forest plots 
displaying the individual and pooled estimates are available in SA6.  
Breast cancer mortality estimates from each RWE method lie relatively close to the pooled 
randomised trial estimates, except for IV1. In contrast, there is some evidence of differences 
between RWE and trial evidence in relation to all-cause mortality, with the PSM estimating 
lower hazard ratios than trials.  
For all RWE methods except PSM Cox, estimates of the hazard ratios for all-cause mortality 
are lower than for BC-specific mortality, in contrast to the trial estimates. This suggests a 
downward bias in the all-cause mortality estimates, as the effect of chemotherapy on all-
cause mortality is expected to be smaller and proportional to its effect on BC mortality. This 
is based on the mechanism of action and was demonstrated in the randomised trial meta-
analysis results.  
Some differences between RWE estimates are large enough to produce differences in the 
combined HRs which may be of clinical importance. Estimates from the IV analyses are 
relatively imprecise in the TR group, which may be due to the relatively small proportion of 
variation in the use of chemotherapy explained by the instruments. Despite our relatively 
large sample sizes, the synthesis of RWE and trial evidence in a random effects meta-
analysis reduces the uncertainty about the HR by only a small amount compared to using 
the randomised trial data alone, irrespective of using the TR or full cohort samples. 
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Table 3 - Comparison of effect sizes (HR, 95% confidence intervals) and pooled estimates from randomised 
trials, RWE (trial represented and RWE full cohort 
?????????????? ????????? ?????????? ?????????
HR? Combined HR? HR? Combined HR?
EBCTCG meta-analysis: Direct evidence newer anthracycline regimens vs placebo?
0.71 (0.62; 0.83)? -? 0.83 (0.73; 0.94)? -
RWE estimates (trial represented)?
RA 0.76 (0.67; 0.87) 0.74 (0.67; 0.82) 0.69** (0.62; 0.77) 0.75 (0.69; 0.81) 
PSM Cox 0.69 (0.57; 0.84) 0.71 (0.63; 0.79) 0.71 (0.61; 0.83) 0.78 (0.71; 0.86) 
PSM LR 0.77 (0.64; 0.93) 0.74 (0.66; 0.82) 0.73 (0.63; 0.85) 0.79 (0.71; 0.87) 
IV1 0.91 (0.70; 1.20) 0.75 (0.66; 0.86) 0.78 (0.61; 1.00) 0.82 (0.73; 0.91) 
IV2 0.85 (0.64; 1.13) 0.74 (0.65; 0.84) 0.74 (0.57; 0.95) 0.81 (0.72; 0.91) 
RWE estimates (full cohort)?
RA 0.82 (0.75; 0.89) 0.79 (0.73; 0.85) 0.77 (0.72; 0.83) 0.78 (0.74; 0.83) 
PSM Cox 0.66 (0.59; 0.74) 0.68 (0.62; 0.75) 0.67** (0.61; 0.74) 0.75 (0.67; 0.85) 
PSM LR 0.68 (0.61; 0.76) 0.69 (0.63; 0.76) 0.67** (0.61; 0.73) 0.76 (0.67; 0.85) 
IV1 0.88* (0.75; 1.02) 0.78 (0.68; 0.89) 0.82 (0.73; 0.92) 0.82 (0.75; 0.90) 
IV2 0.82 (0.71; 0.96) 0.76 (0.69; 0.85) 0.81 (0.72; 0.91) 0.82 (0.75; 0.89) 
???????????????????????????????????????????????????????????????????????????????? ???????????????????????????
??????????????????????????????????????????????? ?????????????????????? ????????????????????????????????????
????????????????????????????????????????????????
Figure 2 - Forest plots; Trial and RWE estimated HR for breast cancer and all-cause mortality 
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???????????
The RWD used in this study is of large size and high quality. Linkage to a range of other 
routine data sets allows an assessment of patient comorbidities that would not be possible 
with registry records alone. Use of an existing, validated prognostic score efficiently uses 
prognostic information in a manner consistent with existing epidemiological evidence. 
We have attempted to be comprehensive and transparent in the application and evaluation 
of RWE methods, rather than simply presenting one method with what we judge the ‘best’ 
result or justification. This guards against the potential for spurious results arising from a 
selective post hoc application of the methods or selective use of a particular specification 
within each method based on the results. Using RWD there is clearly a wider scope for 
creating bias in this way, as compared to using trial data. This is an important analytical 
problem similar to ‘p-hacking’ or a ‘garden of forking paths’ that has been described in other 
settings (21). 
A limitation of this study is that the comparison of real world and clinical trial evidence may 
not directly assess the validity of the real-world evidence. Validating against clinical trials 
could be misleading if the average treatment effect in a trial represented RWD group and the 
actual trial samples differs systematically. At the same time, interpreting the results as 
estimates of systematic differences in treatment effects between trial and real-world 
populations will be unwise if the observational methods lack internal validity.  In this study 
the use of a trial represented population in the RWD should minimise this potential problem. 
Other solutions to this problem could be attempted in future research if additional data are 
available. While we were fortunate that a comprehensive IPD meta-analysis was available, 
this analysis was restricted to using the summary statistics from the published report. This 
limited the degree to which we could match the randomised trial and RWD populations for 
baseline characteristics and treatment protocols or make use of other methods of 
adjustment (22).  Future studies should consider a deeper collaboration with trialists to allow 
more nuanced comparison. Another area that could be explored in future research is the 
design of other tests of internal validity, such as falsification endpoints (23), of RWE 
methods such as IV in this setting. 
  
This analysis would be enhanced if more detailed data were available for specific variables. 
Chemotherapy use was only available as a binary variable, rather than the details of the 
regimens used. Her2 status and trastuzumab use were not available for many observations 
(and not available in any case prior to 2009). 13% of cases were excluded from the analysis 
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due to other missing prognostic data. Another limitation of this analysis is that it relies on 
accurate coding of causes of death on death certificates to ascertain breast cancer deaths. 
This may be less accurate in RWD than in the trial setting, where detailed follow-up to 
ascertain deaths with recurrence of breast cancer has been used. RWE could also be 
enhanced by reporting of effects on multiple alternative causes of death (e.g. breast cancer, 
cardiovascular, other) where such data are available, using an appropriate methodology to 
account for competing risks. This would also more nuanced conclusions regarding the 
potential biases related to each of these outcomes.
????????????
Regression adjustment, PSM and IV were feasible methods for obtaining treatment effect 
estimates from these real-world data while RDD was not. While concordance with 
randomised trial evidence was demonstrated for cause-specific mortality there was some 
indication of bias in estimates of chemotherapy effects on all-cause mortality. We conclude 
that even with large, good quality datasets and careful validation of the assumptions 
underlying these methods, RWE should be interpreted cautiously, in the context of the 
available RCT evidence and with consideration of alternative methods that can be 
implemented using observational data. 
?
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??????????????????????????
??? ??????????????????????????????????????????????????????????????????????????????????????????
?????????????????? ?????????????????????????????????????????????????????????????????????????????????
???????????????????????????
??? ????????????????????????????????????????????????????????????????????????????????????
??????????? ?????????????? ??????????????????????????????? ?????????????????????????
??? ?????????????????????????????????????????? ??????????? ?????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????
???????????????????
??? ?????????????????????? ??????????????????????????????????????????????????????????????????????
???????????????????????? ????????????????????????????
??? ?????????????????????????????????????????????????????????????????????????? ????
????????????????????
???? ???????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????
?????????????????
???? ??????????????????????????????????????????????? ??????????????????????????????????????? ?????
????????????????????????????????????????????????? ??????????????????????????????????????????????
??????????????????????????????????????
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???? ??????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????
???? ?????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????
???? ?????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????
???? ????????????? ???????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????
???? ?????????????? ????????????????????????????????????????????????????????????????????
???? ??????????????????????????????????????????????????????????
???? ?????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????? ???????????????????????????????????????????
????????????????????????
???? ???????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????
???? ??????????????????????????????????????????????????????????????????????????????????????? ????
?????????? ????????? ???????????? ???????????? ?????????????????????????? ??????????????????????
????
???? ???????????????????????????????? ???????????????????????????????????? ?????????????????????
????????????????????????????????????????????????????????????????????????????????
????????????????????
???? ?? ?????????????????????? ????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????
?????????????????????
???? ?????????????????????????????????? ???????????? ????????????????????? ??????????????????????????
?????????????????????????????? ?????????????????????????????????????????????????????????
??????????????????
???? ???????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????
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?????????
?????????????????????????????????????????????????
Prognostic factors available in the registry extract included: age at diagnosis, number of 
lymph nodes examined and number positive, tumour size (maximum pathological diameter 
in mm), tumour histological grade (categorical: 1-3), mode of detection (screen-detected or 
symptomatic), Estrogen receptor (ER) status, Her2 status, chemotherapy use (binary) and 
hormone therapy use (binary). The linked data sets include many variables related to each 
type of healthcare use. This analysis makes use of three specific derived variables:  
1. Total number of inpatient bed days (log transformed) in the previous 5 years. 
2. Any inpatient or day case attendance related to a Charlson Index (1) included 
comorbidity (binary variable) in the previous 5 years. 
3. Total number of prescribed medications in the previous 12 months (log transformed). 
PREDICT 10-year prognostic scores were calculated for each individual woman based on 
their recorded risk factor information using the algorithms supplied by the PREDICT authors 
(version 1.2 and version 2). Data were unavailable for some variables needed as inputs for 
the PREDICT model, these included HER2 status (prior to 2009), trastuzumab use and Ki-67 
status. Ki-67 status is not recorded in these data, as it was not routinely recorded in 
Scotland, therefore all cases were assigned to the “unknown” category for this variable. 
HER2 status is only recorded from 2009. Cases with missing data for HER2 were assigned 
the “unknown” category. The scores include the probability of death from all causes, 
probability of death from breast cancer accounting for competing risk, and adjuvant therapy 
benefit (chemotherapy, hormone therapy and trastuzumab) as the percentage point 
reduction in the probability of all-cause mortality for each adjuvant therapy (‘Benefit scores’).  
Details of the calculation of the prognostic index are available in (2, 3). 
PREDICT provides personalised prognostic information displayed as 5-year and 10-year 
survival estimates both with and without adjuvant therapies (chemotherapy, hormone 
therapy and trastuzumab). Results are presented both in textual format using a frequency 
based description of risk, and graphically in the form of bar charts with percentages labelled 
(http://www.predict.nhs.uk/). The first online version of the tool was published in 2010 (4) 
(v1). A series of updates made since launch have added new prognostic variables and 
refined the algorithm’s predictions. The first update published in 2012 (2), added HER2 
status as a prognostic marker and allowed calculation of Trastuzumab treatment benefit 
estimates (v.1.2). In 2014, the tumour proliferative marker Ki-67 was added as an optional 
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prognostic variable (5) (v1.3). The most recent update, in 2016, refined the model by 
including age at diagnosis in the breast cancer-specific death prediction as well as recoding 
tumour size and nodal status as continuous rather than categorical variables (v2) (3). In this 
study we make use of versions 1.2 and 2. 
Local treatment protocols in Scotland (and in the rest of UK) have defined thresholds, 
derived from international consensus,  for recommending treatments based on estimated 
treatment benefit (personal communication – treatment protocols for NHS Lothian & NHS 
Greater Glasgow & Clyde)(6): 
• <3% (percentage point) reduction in mortality over 10 years: Do not recommend 
adjuvant chemotherapy 
• 3-5% reduction in mortality over 10 years: Discuss adjuvant chemotherapy 
• >5% reduction in mortality over 10 years:  Recommend adjuvant chemotherapy 
Widespread use of local protocols based on explicit thresholds are relatively recent (within 
approximately the last 5 years). National guidelines have considered the idea of threshold 
but have left the precise level implicit with statements such as “Adjuvant anthracycline-
taxane combination chemotherapy should be considered for all patients with breast cancer 
where the additional benefit outweighs risk” (7). Both local protocols and national guidelines 
note the need for shared decision making in this area and do not preclude treatment outside 
of the prescribed thresholds. 
The preceding introduction described the current context of adjuvant therapy decision 
making in Scotland. Treatment decisions in the 2001-2015 period covered by the available 
data were not made under the existing guidelines or with the current PREDICT online tool 
prior to its inception in 2010. However, we believe the existing guidelines and online tool 
may be good proxy measures of the implicit thresholds and treatment benefit estimates of 
past practice. Some evidence exists to suggest similar methods have been in use over this 
period although in a less standardised manner. A survey of UK breast unit lead clinicians 
conducted in 2001/2002 to ascertain use of prognostic scoring systems indicated 
widespread but varied use of such methods. Among the 168 out of 218 units, 53% of units 
stated that a prognostic index was used as part of a formal treatment protocol. Further 
analysis of the treatment protocols of 22 of these units revealed a high degree of variation in 
how prognostic information was used to guide treatment decisions (8). A retrospective study 
of multi-disciplinary team (MDT) decisions conducted in the UK between 2007 and 2011 
assessed concordance between a PREDICT protocol (as above: <3, 3-5,>5%) based 
treatment recommendation and actual treatment recommendation (6). In total, in 91 out of 
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109 cases the MDT recommendation was concordant with what would be suggested by the 
Predict protocol. A higher proportion of discordant cases were observed in the <3% 
predicted treatment benefit group. In this group, 8 out of 14 patients were recommended 
chemotherapy in contradiction to the protocol. 
?
?????????????? ????????
??????????????????????
Regression adjustment (RA) was implemented using Cox regression. Explanatory variables 
in the Cox regression included: chemotherapy use, PREDICT 10-year probability of 
mortality, age at diagnosis, number of positive lymph nodes, pathological tumour size, 
tumour histological grade, mode of detection, ER status, Her2 status, hormone therapy use, 
radiotherapy use, year of diagnosis, Scottish Index of Multiple Deprivation (SIMD) quintile, 
Charlson comorbidity status, log total inpatient bed days and log total outpatient visits (5 
years prior to diagnosis). Interactions of other clinical prognostic factors with ER status were 
also included based on the reported PREDICT modelling process which fits separate models 
for ER+ and ER- groups. In the analysis with breast cancer death as the outcome PREDICT 
10-year probability of breast cancer mortality was used in instead of PREDICT 10-year 
probability of mortality.  
?????????????
Probit regression was used to generate the propensity scores. Predicted probabilities of a 
chemotherapy use for each observation were obtained based on regression of the same set 
of explanatory variables as in the RA analysis on a binary indicator of chemotherapy use.  
Matching of treated and non-treated observations was achieved by nearest-neighbour 
matching on the propensity scores. Three matching methods were investigated: [PSM 1] 
treated observations were matched 1:1 with non-treated observations with replacement (re-
use of non-treated observations), [PSM 2] matching 1:1 without replacement, and [PSM 3] 
limited 1:1 matching with replacement to matching within calipers set to 0.25 standard 
deviations of the logit of the propensity score, as suggested by (9). In all cases matching 
was restricted to observations within the region of common support (only treated 
observations with propensity scores between the maximum and minimum scores in the non-
treated observations were included). Furthermore, the sample was trimmed to observations 
ranging from a propensity score of 0.05 to 0.95 prior to matching.  
To examine the quality of the matches achieved by each matching method, baseline 
covariate balance in the matched treated and non-treated samples was assessed by 
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comparing the means or proportions of baseline covariates.  
Cox regression (PSM Cox) and Peto logrank method (10) (PSM LR) were used to estimate 
hazard ratios for chemotherapy in the matched samples. Proportional hazard was assumed 
based on reported results from the trial meta-analysis which found no evidence against this 
assumption (11, 12), it was assumed this would also hold in the RWD setting. When 
matching with replacement was used observations were weighted accordingly. Confidence 
intervals were calculated by a simple bootstrap of individual cases with 1000 iterations. 
An additional sensitivity analysis was carried out with the proposed instrumental variable 
removed from the set of explanatory variables in the probit regression used to obtain the 
propensity scores. This regression model for propensity scores would be more appropriate if 
the instruments are judged to be valid (13). As the validity of the instruments cannot be 
tested empirically therefore the interpretation of results, and/or weighting given to each 
method’s set of results, must depend on the readers judgement and prior beliefs.   
????????????????????????????????
After considering a number of candidate instruments, two were selected to be used in 
treatment effect estimation: PREDICT benefit score (IV 1) and the PREDICT benefit score 
interaction with a post 2010 dummy variable (IV 2). The first specification is more efficient 
(greater statistical power) but with greater potential bias while the second is less efficient but 
has less potential for bias. See the section below (SA2) for instruments considered and 
reasons for selection of the instruments. IV1 relies on the benefit score being independent 
from expected survival conditional on the prognostic score and chemotherapy use. As 
benefit score is the difference in expected survival with and without chemotherapy this 
should be the case by construction, however it requires the prognostic model to be well 
calibrated. IV2 exploits the introduction of the PREDICT online tool and this assumes that 
the ability to access this information influenced the decisions made across the range of 
PREDICT benefit scores. 
PREDICT scores have the potential to provide a valid instrumental variable but this relies on 
the prognostic model being perfectly calibrated so that all information about survival 
available from the input variables is captured by the prognostic score, to guarantee that the 
benefit score (which is a function of these same inputs) is independent from survival without 
treatment. An instrument that does not rely on this assumption can be created by interacting 
PREDICT benefit score with a post-2010 dummy variable. This exploits the change in the 
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relationship between benefit score and the adjuvant therapy decision that is expected to 
occur when this information is available to clinicians and patients compared to when it was 
not available. A possible limitation of the second approach is that this instrument is likely to 
be weaker, in the sense of having a smaller association with the probability of receiving 
chemotherapy. 
The two-stage residual inclusion (2SRI) strategy was used in this study (14). This method 
can provide consistent estimates of the treatment effect in situations with non-linear first and 
second stage regressions (due to limited dependent variables). In this case the first stage 
was estimated by logistic regression and the second stage was estimated by Cox 
regression. Confidence intervals were calculated by a simple bootstrap of individual cases 
with 1000 iterations. A Wald test was used to assess the strength of the proposed 
instruments in the first stage regression. The assumptions of independence of the instrument 
from unmeasured confounding variables and that the instrument does not affect outcomes 
expect through the effect on treatment status cannot be empirically tested. A judgement on 
their validity in this case must be reached by consideration of theory and the understanding 
of the decision making process. 
?????????????
Before considering estimation of the RDD treatment effect an assessment of whether the 
assumptions were met in this scenario was made. For full details of assumptions assessed 
see the section below (SA2). 
Assessment of the continuity assumption [A3] was made for both potential assignment 
variables (PREDICT v1.2 and v2) by a combination of visual inspection of histograms and 
covariate balance tests for observations +/-0.5% above and below each threshold (3% and 
5% probability of chemotherapy benefit). Assumption [A1] was tested by visual inspection of 
binned scatterplots of chemotherapy use against the assignment variable in two ways; [1] 
scatterplots with simple binning by quantiles (20 quantiles) and [2] an automated procedure 
for selecting equally spaced bins using the weighted integrated mean square error (WIMSE) 
(15). In addition, the plots produced using method [2] also include polynomial regression fit 
by an automated procedure (15).  
??????????????????????????????????????
Table 2.1 Candidate instrumental variables 
Candidate variable Notes 
Temporal:
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(all potentially implemented using binary, 
multivalue categorical or continuous 
variables related to date of treatment) 
HER2/trastuzumab 2006 June – SMC approval 
2008/9 – roll-out/recorded in data 
 ‘3rd generation’ chemotherapy (taxanes) 2005/6, 2007 Cochrane review 
PREDICT online tool 2010, 2012 v2 
Aromatase Inhibitors (AIs)  2005 trials report, 2007 roll-out 
Sentinel Node Biopsy (SNB) 2003 
No dissection of some negative node SNB 
(guideline?) 
2011 
Screening extension trial (47-73) 2007 
Screening double reading 2011 
Digital mammography 2010 gradual 
First screening cohort exits programme – 
max population screening prevalence 
reached 
2008 
Regional:
Territorial health board (HB) of residence Can be interacted with the events above to 
use variation in speed of adoption 
Specific selected health boards Can be interacted with the events above to 
use variation in speed of adoption 
Time diagnosis-to-surgery, time surgery-to-
chemo/hormone/radiotherapy – HB level 
mean  
Can be calculated by period or as moving 
average to give measure of demand 
pressure 
Patient level variables:
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Urban/rural classification Can influence convenience of chemotherapy
Adjusting for deprivation is important 
Age in relation to specific boundaries  70/75/80 – candidates for ages at which “old 
age as a contraindication for chemotherapy 
might be applied”. Known bias for ages that 
are multiples of 5. 
PREDICT scores 
- Prognostic score: probability of 
survival/mortality at X years without 
adjuvant treatment 
- Benefit score: percentage benefit 
from chemotherapy 
- Higher order transforms, interactions 
or discontinuities 
- Use treatment benefit score 
conditioned on prognostic score. If 
model is perfectly calibrated this is 
guaranteed instrument because 
benefit score is independent from 
outcome by design, all effect of 
benefit score determinants on the 
outcome are captured in the 
prognostic score.  
- Interaction of the chemotherapy 
benefit score with a post 2010 
dummy variable. This takes 
advantage of effect of the 
introduction of PREDICT on clinical 
practice. 
- Use the apparent discontinuity/non-
linearity in chemo uptake in 1-2% 
benefit range rather than the 
expected discontinuity at 3%. Extra 
caution would be needed to protect 
against chance finding. 
?????????????????????????????????????
Individual candidate temporal trend variables or event dummy variables were rejected as 
instruments because of the high potential for confounding by other contemporaneous 
events. There are too many changing factors in breast cancer incidence and treatment in 
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this time period to reliably estimate the effect of a single factor on adjuvant chemotherapy 
use. These include the introduction of new therapies such aromatase inhibitors and targeted 
therapy with Trastuzumab, changes in the national breast screening programme age range 
and introduction of digital mammography, changing surgical practices such as greater use of 
sentinel lymph node biopsy, and long term trends in the incidence of different molecular 
subtypes of breast cancers (ER+ and ER-) related to factors such as past use of hormone 
replacement therapy. 
Regional variation was explored at the health board level (geographical units of National 
Health Service organization roughly equivalent to counties usually with a single large 
hospital delivering breast cancer care), however relatively little variation in adjuvant 
chemotherapy use was observed after controlling for other factors (prognostic factors and 
deprivation status). Therefore, regional variables related to provider preferences were not 
considered viable as instruments. Urban/rural status and age-based variables were rejected 
as being unlikely to satisfy the exclusion restriction. 
PREDICT scores have the potential to provide a valid instrumental variable but this relies on 
the prognostic model being perfectly calibrated so that all information about survival 
available from the input variables is captured by the prognostic score, to guarantee that the 
benefit score (which is a function of these same inputs) is independent from survival without 
treatment. An instrument that does not rely on this assumption can be created by interacting 
PREDICT benefit score with a post-2010 dummy variable. This exploits the change in the 
relationship between benefit score and the adjuvant therapy decision that is expected to 
occur when this information is available to clinicians and patients compared to when it was 
not available. A possible limitation of the second approach is that this instrument is likely to 
be weaker, in the sense of having a smaller association with the probability of receiving 
chemotherapy. 
Two specifications were selected to be used in treatment effect estimation: PREDICT benefit 
score and the PREDICT benefit score interaction with a post 2010 dummy variable. The first 
specification is more efficient (greater statistical power) but with greater potential bias while 
the second is less efficient but has less potential for bias. 
??????????????????????????????????????????????????????
Two broad classes of RDD exist (16). The first class is when the threshold fully determines 
treatment allocation, i.e. 100% of patients are exposed to treatment above the threshold, and 
none below; this is called a sharp RDD. The second class is when the treatment rule is less 
strict, and treatment may occur on either side of the threshold. However, the probability of 
being treated sharply increases at the threshold. This is called a fuzzy RDD. In this study, as 
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is common when clinical guidelines and decision aids are in use, we have an opportunity to 
apply a fuzzy RDD. 
In fuzzy RDD analysis there is an assignment variable ? with a threshold ??, the treatment 
status ??) of each individual ??? is partially determined by the level of ? and there are treated 
and untreated individuals on both sides of the threshold. The probability of treatment is 
determined by a different function (i.e. is discontinuous) on either side of the threshold (16):  
????? ? ????? ? ??????????? ? ???????????? ? ?? ? ?????? ? ??????
When the assumptions for RDD are met the identified causal effect is typically interpreted as 
a “local average treatment effect” (LATE) (17). It is sometimes also called the complier 
average treatment effect or complier average causal effect (CATE/CACE) (18).  
The assumptions required for a RDD to yield an unbiased estimate relate to the assignment 
mechanism, the relationship between assignment and outcomes and the relationship 
between the treatment threshold and potential confounding factors. Following the exposition 
provided by Geneletti et al (19) these can be explained based on the concept of conditional 
independence. The context is as above; there is an assignment variable ? with a threshold 
??, patients are recommended treatment, or more likely to be recommended treatment, if the 
level of ? is greater than ???
[1] Firstly, the assignment to treatment must be influenced by the level of the assignment 
variable being over the threshold; or equivalently, a threshold indicator variable ? (1 if ? ?? , 
0 otherwise) is not independent of treatment status variable ?: 
????? ?? ? ????????
This assumption is tested by visual assessment of the discontinuity and estimation of the 
first-stage regression. 
[2] A second assumption is that the level of threshold is independent of the characteristics of 
the individual (potential confounders ?)  at any level of the assignment variable. Conditional 
on the assignment variable, ? is independent from ?: 
????? ???? ? ?????????????
The assumption would not hold if different thresholds were applied (e.g. to men and women) 
and this is not accounted for in the analysis (e.g. by separating the analysis). This 
assumption is verified by external knowledge of the thresholds.   
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
25 
[3] Continuity assumption (exchangeability assumption). To identify the discontinuity in 
outcome as being causally related to the indicator variable it is also necessary to assume 
continuity of the expected outcome conditional on the assignment variable (in both treated 
and non-treated cases). This can be stated as: 
?????? ? ? ?? ?? ??????????????????????????? ? ????
The assumption would not be valid in cases where individuals can manipulate their 
assignment scores (without error) so as to be placed on the side of the threshold that they 
wish. In this scenario, the outcome is no longer independent from the threshold indicator 
variable conditional on the assignment variable because the observed assignment variable 
scores are not the true scores. Visual inspection of histograms and formal testing for a 
discontinuity in the density function of the assignment variable have been suggested to 
investigate this assumption (20). Another means of checking this assumption is to perform 
tests of covariate balance between groups of observations above and below, and close to, 
the threshold. 
Another case in which the continuity assumption may not hold is when the assignment 
variable is a categorical variable with a small number of discrete values. In such cases a 
discontinuity may exist that could be incorrectly attributed as a treatment effect. This can be 
determined based on knowledge of the assignment variable and visual inspection of 
histograms of the assignment variable.  
[4] It is assumed that outcome ? is independent from the threshold indicator ? conditional on 
the treatment status, assignment variable and confounding variables: 
????? ???? ?? ?? ? ??????? ?? ????????? ?? ??
This assumption guarantees that the effect of ? on the outcome ? is due entirely to the effect 
of  ? on ? and the resulting effect of the change in ? on ?.  This assumption would not be 
met if the threshold also influences treatment decisions for other therapies that have effects 
on the same outcome. 
To check this assumption ‘placebo’ analysis could be undertaken replacing the treatment 
variable with other treatments that are assumed not to be influenced by the threshold. 
[5] In the case of the fuzzy design only, in which treatment is not fully determined by ?, it is 
necessary to assume that the assignment rule is not reversed for some cases, i.e. Patients 
are treated only if below threshold rather than only if above threshold. This is unlikely to be 
important in the scenarios considered in health care. Guidelines may not be followed but are 
unlikely to be followed in reverse. 
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The assumptions of threshold being set independently of potential confounders [A2], that the 
threshold only influences the outcome through the effect on the treatment of interest [A4], 
and that the assignment rule is never reversed [A5] were considered met based on 
knowledge of the clinical scenario. 
? ?
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??????????????????????????????????????????????????????????????????????
Figure 3.1 Propensity score histograms 
Left: trial represented population, Right: Full cohort population, 0: no chemotherapy, 1: chemotherapy
Table 3.1 Balance PSM V1 – 1:1 Nearest Neighbour 
Variable Trial Represented Full cohort 
 Mean 
untreated 
Mean 
treated 
P NH: 
m1=m2 
SMD Mean 
untreated 
Mean 
treated 
P NH: 
m1=m2 
SMD 
Age 56.06 55.55 <0.001 0.063 57.32 55.91 <0.001 0.142 
PREDICT 10y 
mort. 
0.38 0.38 0.031 0.035 0.38 0.36 <0.001 0.085 
Screen detected 0.31 0.31 0.669 0.007 0.28 0.28 0.435 -0.011 
No. Positive nodes 2.55 2.5 0.508 0.011 2.07 2.14 0.208 -0.017 
Tumour size 26.18 26.01 0.538 0.01 26.09 25.14 <0.001 0.058 
grade 2 0.38 0.39 0.048 -0.033 0.35 0.39 <0.001 -0.088 
grade 3 0.59 0.56 0.001 0.054 0.62 0.57 <0.001 0.09
ER + 0.73 0.72 0.171 0.023 0.74 0.76 0.002 -0.042 
log inpatient days 0.26 0.24 0.191 0.022 0.36 0.3 <0.001 0.069 
log outpatient apts 1.08 1.06 0.19 0.022 1.16 1.09 <0.001 0.072 
Charlson (0/1) 0 0 0 0 0.05 0.05 0.01 0.035 
SIMD 3.07 3.03 0.119 0.026 2.98 3.06 <0.001 -0.05 
hormone therapy 0.62 0.63 0.414 -0.013 0.63 0.65 0.001 -0.043 
radiotherapy 0.67 0.69 0.001 -0.057 0.65 0.7 <0.001 -0.117 
P NH m1 = m2: p-value for test of null hypothesis mean 1 = mean 2  
SMD: Standardised mean difference 
Table 3.2 Balance PSM V2 – 1:1 Nearest Neighbour no replacement 
Variable Trial Represented Full cohort 
 Mean 
untreated 
Mean 
treated 
P NH: 
m1=m2 
SMD Mean 
untreated 
Mean 
treated 
P NH: 
m1=m2 
SMD 
Age 59.62 60.09 0.031 -0.064 59.05 55.91 <0.001 0.308 
PREDICT 10y 
mort. 
0.31 0.31 0.24 -0.035 0.27 0.36 <0.001 -0.402 
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Screen detected 0.45 0.46 0.534 -0.018 0.38 0.28 <0.001 0.207 
No. Positive 
nodes 
1.66 1.61 0.543 0.018 0.89 2.14 <0.001 -0.359 
Tumour size 21.85 22.62 0.042 -0.06 20.61 25.14 <0.001 -0.339 
grade 2 0.46 0.5 0.025 -0.066 0.59 0.39 <0.001 0.401 
grade 3 0.37 0.38 0.299 -0.031 0.33 0.57 <0.001 -0.476 
ER + 0.81 0.8 0.207 0.037 0.88 0.76 <0.001 0.325 
log inpatient days 0.35 0.35 0.806 -0.007 0.36 0.3 <0.001 0.071 
log outpatient apts 1.11 1.12 0.742 -0.01 1.1 1.09 0.316 0.014 
Charlson (0/1) 0 0 0 0 0.06 0.05 0.001 0.047 
SIMD 3 2.95 0.262 0.033 3.11 3.06 0.002 0.042 
hormone therapy 0.75 0.72 0.053 0.057 0.8 0.65 <0.001 0.33 
radiotherapy 0.67 0.62 <0.001 0.105 0.69 0.7 0.006 -0.037 
Table 3.3 Balance PSM V3 – 1:1 Nearest Neighbour no replacement within calipers
Variable Trial Represented Full cohort 
 Mean 
untreated 
Mean 
treated 
P NH: 
m1=m2 
SMD Mean 
untreated 
Mean 
treated 
P NH: 
m1=m2 
SMD 
Age 58.97 59.02 0.819 -0.007 59.03 58.8 0.294 0.022 
PREDICT 10y 
mort. 
0.32 0.33 0.66 -0.014 0.33 0.32 0.011 0.053 
Screen detected 0.42 0.43 0.452 -0.024 0.33 0.36 0.002 -0.065 
No. Positive 
nodes 
1.78 1.86 0.497 -0.022 1.45 1.37 0.247 0.024 
Tumour size 22.93 23.34 0.348 -0.03 22.85 23.2 0.212 -0.026 
grade 2 0.48 0.45 0.112 0.051 0.44 0.46 0.017 -0.05
grade 3 0.42 0.42 0.896 0.004 0.51 0.48 0.001 0.071
ER + 0.78 0.79 0.635 -0.015 0.81 0.83 0.031 -0.045 
log inpatient days 0.3 0.32 0.33 -0.031 0.38 0.38 0.758 0.006 
log outpatient apts 1.1 1.13 0.337 -0.031 1.13 1.13 0.998 0 
Charlson (0/1) 0 0 0 0 0.06 0.05 0.196 0.027 
SIMD 3.02 2.96 0.22 0.04 3.05 3.04 0.871 0.003 
hormone therapy 0.72 0.71 0.721 0.012 0.73 0.74 0.436 -0.016 
radiotherapy 0.67 0.64 0.083 0.056 0.69 0.67 0.108 0.034 
Table 3.4 PSM Cox regression results 
   All cause mortality Breast cancer mortality
Group
Matching
method
N
treated deaths HR 95% CI: deaths HR 95% CI: 
Trial PSM 1 14756 2358 0.67 (0.55, 3182 0.63 (0.54, 
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Represented 0.85) 0.77)
PSM 2 4586 475 0.75 (0.62, 
0.91)
759 0.72 (0.63, 
0.84)
PSM 3 3830 431 0.69 (0.59, 
0.86)
648 0.66 (0.59, 
0.8)
Full Cohort PSM 1 21840 3463 0.71 (0.57, 
0.76)
4950 0.63 (0.54, 
0.68)
PSM 2 21840 2772 1.19 (1.08, 
1.26)
4169 0.94 (0.88, 
0.99)
PSM 3 9178 1267 0.71 (0.64, 
0.8)
1905 0.67 (0.63, 
0.76)
HR: Hazard ratio for chemotherapy CI: confidence interval N/A: non-applicable 
Table 3.5 PSM Cox regression results – sensitivity analysis without instrumental 
variable 
   All cause mortality Breast cancer mortality
Group
Matching
method
N
treated deaths HR 95% CI: deaths HR 95% CI: 
Trial 
Represented
PSM 1 14948 3376 0.56 (0.54, 
0.77) 
2573 0.57 (0636, 
0.86) 
PSM 2 4616 475 0.74 (0.64, 
0.87) 
487 0.78 (0.66, 
0.96) 
PSM 3 3888 431 0.69 (0.6, 
0.83) 
442 0.72 (0.63, 
0.92) 
Full Cohort PSM 1 22342 5159 0.6 (0.54, 
0.68) 
3648 0.66 (0.56, 
0.75) 
PSM 2 22342 4240 0.93 (0.88, 1) 2819 1.19 (1.1, 
1.29) 
PSM 3 9372 1930 0.71 (0.65, 
0.78) 
1262 0.77 (0.67, 
0.84) 
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Table 4.1 IV regressions 1st and 2nd stage results by sample 
Trial represented Full cohort
Specification Coefficient / HR
(P Value)
95% CI Coefficient /
HR 
(P Value)
95% CI
All-cause mortality     
Instrument 1:     
PREDICT benefit score 
[1st stage] 
0.295  
(P<0.001) 
(0.222, 0.369) 0.492 
(P<0.001) 
(0.435, 0.549) 
Chemotherapy 
[2nd stage] 
0.77 (0.62, 1) 0.81 (0.73, 0.92) 
Instrument 2:     
PREDICT benefit 
score*post-2010 
[first stage] 
0.141  
(P<0.001) 
(0.088, 0.195) 0.094 
(P<0.001) 
(0.059, 0.129) 
Chemotherapy 
[2nd stage] 
0.73 (0.58, 0.96) 0.8 (0.72, 0.91) 
Breast Cancer Mortality     
Instrument 1:     
PREDICT benefit score 
[1st stage] 
0.295 (P<0.001) (0.222, 0.369) 0.457 
(P<0.001) 
(0.398, 0.515) 
Chemotherapy 
[2nd stage] 
0.91 (0.7, 1.2) 0.88 (0.77, 1.03) 
Instrument 2:     
PREDICT benefit 
score*post-2010 
[first stage] 
0.142 (P<0.001) (0.088, 0.195) 0.094 
(P<0.001) 
(0.059, 0.129) 
Chemotherapy 
[2nd stage] 
0.79 (0.62, 1.02) 0.82 (0.72, 0.96) 
Other explanatory variables omitted from table 
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Figure 5 shows histograms over the full range and restricted to the region of the thresholds 
for PREDICT v1.2. Figure 6 shows the same for PREDICT version 2. The continuity 
assumption appears to not be met for PREDICT v1.2 due to the high density of observation 
immediately following the 3% threshold and the high density of observations immediately 
preceding the 5% threshold. The existence of many peaks and troughs across the whole 
distribution, along with details of the construction of the score, suggests that this is probably 
due to the dominance of the categorical variables in the algorithm which generates the 
scores. The continuity assumption appears to be met for PREDICT v2 because the 
histogram is relatively smooth in the region of the thresholds. PREDICT version 1.2 was 
eliminated as a candidate assignment variable based on this assessment. 
Figure 5.1 Histograms, PREDICT version 1.2 chemotherapy benefit, full range and 
region of thresholds 
Figure 5.2 Histograms, PREDICT version 2 chemotherapy benefit, full range and 
region of thresholds 
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Baseline covariate balance around the 3% threshold is assessed in table 11 and around the 
5% threshold in table 12. Many baseline covariates are inputs to the PREDICT model and 
therefore highly correlated with the assignment variable because PREDICT chemotherapy 
benefit scores are a complex function of these inputs. PREDICT 10-year survival scores and 
the prognostic input variables are significantly different on either side of threshold. This is as 
expected and does not invalidate the RDD method. Two important baseline covariates that 
are not inputs to the PREDICT model are Charlson comorbidity and inpatient bed days, 
these are approximately balanced on either side of the threshold. This is supportive of the 
continuity assumption. 
Table 5.1 Baseline covariate balance around 3% threshold 
Variable Below
(-0.5%)
Above
(+0.5%)
Below
(-0.5%)
Above
(+0.5%)
N N Mean or % Mean or % Statistical
test 
Prognostic – in 
PREDICT  
     
Age 2,538 2,307 61.1 60.6  
Screen detected 
(%) 
2,536 2,305 24.3 19.8  
Tumour size 2,538 2,307 23.4 25.1  
Number of 
nodes positive 
2,538 2,307 0.7 1  
Grade   1 (%) 2,524 2,293 1.9 1.2  
2   45 36  
3   53.1 62.8  
ER status + (%) 2,538 2,307 95.4 86.8  
PREDICT 10-
year survival 
2,538 2,307 66.1 62.9 T test 
P < 0.0001 
Prognostic – Not 
in PREDICT 
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Charlson 
comorbidity (%) 
2,538 2,307 6.7 6.2 Pearson chi-
sq. 
P = 0.410 
Inpatient bed 
days, all 5 years 
prior 
2,538 2,307 2.7 2.5 T test 
P = 0.4497 
Table 5.2 Baseline covariate balance around 5% threshold 
Variable Below
(-0.5%)
Above
(+0.5%)
Below
(-0.5%)
Above
(+0.5%)
N N Mean or % Mean or % Statistical
test 
Prognostic – in 
PREDICT  
     
Age 1,856 1,363 61.9 62.5  
Screen detected 
(%) 
1,847 1,346 15 14.4  
Tumour size 1,856 1,363 27.9 30.9  
Number of 
nodes positive 
1,856 1,363 1.8 2.7  
Grade   1 (%) 1,849 1,360 0.5 0.2  
2   22.6 22.6  
3   76.9 77.2  
ER status + (%) 1,856 1,363 48.7 52.8  
PREDICT 10-
year survival 
1,856 1,363 53.5 48.3 T test 
P < 0.0001 
Prognostic – Not 
in PREDICT 
     
Charlson 
comorbidity (%) 
1,856 1,363 6.3 7 Pearson chi-
sq. 
P = 0.5667 
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Inpatient bed 
days, all 5 years 
prior 
1,856 1,363 3.5 3 T test 
P = 0.3130 
Figure 5.3 - Binned scatterplot (simple) PREDICT chemotherapy benefit score and 
chemotherapy use, trial represented 
Figure 5.4 - Binned scatterplot (WIMSE) - PREDICT chemotherapy benefit and 
chemotherapy use, trial represented, 3% and 5% thresholds 
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